RECORD // Company

Rocket Pharmaceuticals, Inc.

Formerly: INOTEK PHARMACEUTICALS CORP

Built 2026-11-22T00:25:00Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (2)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Rocket Pharmaceuticals Inc. · Ctgov · same registered legal name as 'ROCKET PHARMACEUTICALS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ROCKET PHARMACEUTICALS INC · Epa echo · same registered legal name as 'ROCKET PHARMACEUTICALS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ROCKET PHARMACEUTICALS (NY) · Ny corps · exact name match to 'ROCKET PHARMACEUTICALS, INC.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • ROCKET PHARMACEUTICALS, LTD. · Ny corps · exact name match to 'ROCKET PHARMACEUTICALS, INC.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

8 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001193125-26-458320

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Net income (loss)$-49,234,0003 months ended 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Interest expense$473,0003 months ended 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Cash and cash equivalents$95,470,000at 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Debt due in the next 12 months$0at 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Debt due in year 2$0at 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Debt due in year 3$15,894,000at 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error
Debt due in year 4$19,106,000at 2026-09-3010-Q2026-11-120001193125-26-4583202026-11-22 00:25 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001281895
Ticker
RCKT
CUSIP
77313F106
Record ID
sx:sec:0001281895

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

36 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 00:25 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-22 00:25 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-22 00:25 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-22 00:25 UTCReport an error
Business address350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 101182026-11-20SEC EDGAR company profile2026-11-22 00:25 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 00:25 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:25 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-223,123,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:25 UTCReport an error
Total assets (at 2025-12-31)$330,449,0002025-12-3110-K, XBRL Assets2026-11-22 00:25 UTCReport an error
Stockholders' equity (at 2025-12-31)$277,221,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:25 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$77,558,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:25 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-190,014,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:25 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$440,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:25 UTCReport an error
Operating lease liabilities (at 2025-12-31)$3,603,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:25 UTCReport an error
Form D total offering amount (D/A filed 2011-07-19)$23,600,0002011-07-19D/A2026-11-22 00:25 UTCReport an error
Form D total amount sold (D/A filed 2011-07-19)$23,600,0002011-07-19D/A2026-11-22 00:25 UTCReport an error
Form D industry groupPharmaceuticals2011-07-19D/A2026-11-22 00:25 UTCReport an error
Form D revenue rangeDecline to Disclose2011-07-19D/A2026-11-22 00:25 UTCReport an error
Form D date of first sale2010-06-092011-07-19D/A2026-11-22 00:25 UTCReport an error
8-K Item 2.02 (filed 2026-11-12)Results of Operations and Financial Condition. On November 12, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain financial information for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as…2026-11-12SEC EDGAR 8-K 0001140361-26-043434 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
8-K Item 1.01 (filed 2026-10-06)Entry into a Material Definitive Agreement. Loan and Security Agreement On September 30, 2026, Rocket Pharmaceuticals, Inc. (the “Company”), together with its subsidiaries Spacecraft Seven, LLC and Zebrafish Merger Sub II, LLC (together with the Company, “Borrower”), entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities from time to time party thereto (collectively, the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacities, the “Agent”), providing for up to five tranches of senior…2026-10-06SEC EDGAR 8-K 0001140361-26-038818 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
8-K Item 2.03 (filed 2026-10-06)Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 above is incorporated by reference into this Item 2.03.2026-10-06SEC EDGAR 8-K 0001140361-26-038818 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
8-K Item 3.02 (filed 2026-10-06)Unregistered Sales of Equity Securities. The information set forth under Item 1.01 above regarding the issuance of the Warrants is incorporated by reference into this Item 3.02. The Warrants and the shares of Common Stock issuable upon exercise of the Warrants have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving a public offering. The Lenders represented that they were “accredited investors” as defined in Regulation D under the Securities Act and that they were acquiring the…2026-10-06SEC EDGAR 8-K 0001140361-26-038818 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
8-K Item 7.01 (filed 2026-10-06)Regulation FD Disclosure. On October 6, 2026, the Company issued a press release announcing the entry into the Loan Agreement with Hercules, a copy of the which is furnished as Exhibit 99.1 hereto. Additionally, the Company prepared an investor presentation providing certain updates on the Company’s Danon Disease Program used in a corporate webinar on October 6, 2026, which is furnished as Exhibit 99.2 hereto and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the…2026-10-06SEC EDGAR 8-K 0001140361-26-038818 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
8-K Item 7.01 (filed 2026-09-15)Regulation FD Disclosure. On September 15, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) issued a press release announcing alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease, including the recalibrated dose, 12-patient pivotal population and established 12-month co-primary endpoints. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…2026-09-15SEC EDGAR 8-K 0001140361-26-036563 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
8-K Item 5.02 (filed 2026-08-27)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Severance and Change in Control Program On August 21, 2026, the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company” or “Rocket”) adopted the Rocket Pharmaceuticals, Inc. Severance and Change in Control Program (the “Program”). The Program provides severance benefits to eligible employees of the Company, including its executive officers, in connection with certain qualifying terminations of employment, including terminations occurring in connection with a change in control of the Company. All Rocket employees in the…2026-08-27SEC EDGAR 8-K 0001140361-26-034689 (text as filed, excerpt)2026-11-22 00:25 UTCReport an error
Largest institutional holder #1 (13F as filed): RTW INVESTMENTS, LP$60,492,1802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$33,939,9512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$19,870,3132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #4 (13F as filed): CITIGROUP INC$16,640,1842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #5 (13F as filed): MARSHALL WACE, LLP$13,780,0752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #6 (13F as filed): MILLENNIUM MANAGEMENT LLC$13,681,1762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #7 (13F as filed): Newtyn Management, LLC$13,680,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #8 (13F as filed): MAVERICK CAPITAL LTD$13,419,9532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #9 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$12,942,6042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error
Largest institutional holder #10 (13F as filed): AQR CAPITAL MANAGEMENT LLC$11,580,6752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:25 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.